Tags

Type your tag names separated by a space and hit enter

Leishmaniasis: treatment updates and clinical practice guidelines review.
Curr Opin Infect Dis. 2015 Oct; 28(5):426-37.CO

Abstract

PURPOSE OF REVIEW

This review summarizes recent important and interesting articles investigating the challenging treatment of the parasitic infection, leishmaniasis. In addition, it compares and contrasts leishmaniasis clinical practice treatment guidelines.

RECENT FINDINGS

Studies show that, in contrast to experience in India, visceral leishmaniasis in East Africa requires higher doses of liposomal amphotericin for effective treatment results and that pentavalent antimonial drugs remain efficacious. A retrospective study of visceral leishmaniasis in organ transplant patients suggests that there may be a role for secondary prophylaxis after treatment akin to HIV coinfection recommendations. The pros and cons of oral therapy with miltefosine, which cuts across leishmaniasis syndromes in its spectrum, are discussed. Cutaneous leishmaniasis clinical practice guidelines vary, although the recent European guidelines favor species-directed therapy.

SUMMARY

Leishmaniasis remains a neglected tropical disease, with a need for additional clinical trials with better design and reported endpoints to lead evidence-based treatment recommendations--especially in cutaneous leishmaniasis and leishmaniasis in the immunocompromised host.

Authors+Show Affiliations

aWalter Reed National Military Medical Center bUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26312442

Citation

Copeland, Nathanial K., and Naomi E. Aronson. "Leishmaniasis: Treatment Updates and Clinical Practice Guidelines Review." Current Opinion in Infectious Diseases, vol. 28, no. 5, 2015, pp. 426-37.
Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis. 2015;28(5):426-37.
Copeland, N. K., & Aronson, N. E. (2015). Leishmaniasis: treatment updates and clinical practice guidelines review. Current Opinion in Infectious Diseases, 28(5), 426-37. https://doi.org/10.1097/QCO.0000000000000194
Copeland NK, Aronson NE. Leishmaniasis: Treatment Updates and Clinical Practice Guidelines Review. Curr Opin Infect Dis. 2015;28(5):426-37. PubMed PMID: 26312442.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Leishmaniasis: treatment updates and clinical practice guidelines review. AU - Copeland,Nathanial K, AU - Aronson,Naomi E, PY - 2015/8/28/entrez PY - 2015/8/28/pubmed PY - 2016/2/24/medline SP - 426 EP - 37 JF - Current opinion in infectious diseases JO - Curr Opin Infect Dis VL - 28 IS - 5 N2 - PURPOSE OF REVIEW: This review summarizes recent important and interesting articles investigating the challenging treatment of the parasitic infection, leishmaniasis. In addition, it compares and contrasts leishmaniasis clinical practice treatment guidelines. RECENT FINDINGS: Studies show that, in contrast to experience in India, visceral leishmaniasis in East Africa requires higher doses of liposomal amphotericin for effective treatment results and that pentavalent antimonial drugs remain efficacious. A retrospective study of visceral leishmaniasis in organ transplant patients suggests that there may be a role for secondary prophylaxis after treatment akin to HIV coinfection recommendations. The pros and cons of oral therapy with miltefosine, which cuts across leishmaniasis syndromes in its spectrum, are discussed. Cutaneous leishmaniasis clinical practice guidelines vary, although the recent European guidelines favor species-directed therapy. SUMMARY: Leishmaniasis remains a neglected tropical disease, with a need for additional clinical trials with better design and reported endpoints to lead evidence-based treatment recommendations--especially in cutaneous leishmaniasis and leishmaniasis in the immunocompromised host. SN - 1473-6527 UR - https://www.unboundmedicine.com/medline/citation/26312442/Leishmaniasis:_treatment_updates_and_clinical_practice_guidelines_review_ DB - PRIME DP - Unbound Medicine ER -